Overview

A class action lawsuit has been filed against BioAge Labs, Inc. (“BioAge” or the “Company” (NASDAQ: BIOA) and certain of the Company’s former senior executive officers alleging violations of the federal securities laws.  The BioAge class action lawsuit is brought on behalf of all persons and entities who purchased or otherwise acquired BioAge’s stock pursuant and/or traceable to the Company’s registration statement for the initial public offering held on or about September 26, 2024 (the “IPO”).  Investors have until March 10, 2025 to seek appointment as lead plaintiff in the BioAge class action lawsuit.

BioAge introduced itself to investors during its IPO as a clinical-stage biopharmaceutical company that develops therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging.  BioAge’s lead product candidate, azelaprag, is an orally available small molecule agonist of the apelin receptor APJ.  Apelin is an exercise-induced signaling molecule (exerkine) that acts on APJ and has the potential to recapitulate the metabolic benefits of exercise.

The BioAge class action lawsuit alleges that Defendants’ IPO documents highlighted their collaboration with Eli Lilly and Company on the STRIDES clinical trial, testing azelaprag in combination with tirzepatide to demonstrate enhanced weight loss in obese individuals aged 55 and over.  The trial aimed to establish proof of concept, with a primary endpoint of weight loss at 24 weeks and anticipated topline results in the third fiscal quarter of 2025.  Lilly supplied tirzepatide and provided trial design and execution advice through its Chorus program.

BioAge completed its IPO on September 27, 2024, raising $227.7 million by selling 12.65 million shares at $18 each.  However, on December 6, 2024, BioAge announced it was discontinuing the STRIDES Phase 2 trial after liver toxicity (liver transaminitis) was observed in participants receiving azelaprag, despite no prior indications of such issues in eight Phase 1 studies.  Following this announcement, BioAge’s stock price plummeted from $20.09 per share on December 6 to $4.65 per share on December 7, 2024.

Plaintiff and other investors who purchased BioAge stock during the IPO allege they relied on false or materially misleading information about the STRIDES trial.  They seek compensation for the significant losses incurred as a result of Defendants’ actions and statements.

*          *          *

If you purchased or otherwise acquired BioAge’s stock pursuant and/or traceable to the Company’s registration statement for the IPO held on or about September 26, 2024, and you wish to serve as lead plaintiff in this lawsuit, we encourage you to submit your information to DiCello Levitt LLP via the form on this page. 

You can also contact DiCello Levitt partner Brian O’Mara by calling (888) 287-9005 or at [email protected]. 

The deadline to apply to the Court to serve as lead plaintiff in the BioAge class action lawsuit is March 10, 2025.